- Home
- BPMC vs MAC Comparison
BPMC vs MAC Comparison
Compare BPMC & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPMC
- MAC
- Stock Information
- Founded
- BPMC 2008
- MAC 1964
- Country
- BPMC United States
- MAC United States
- Employees
- BPMC N/A
- MAC N/A
- Industry
- BPMC Biotechnology: Pharmaceutical Preparations
- MAC Real Estate Investment Trusts
- Sector
- BPMC Health Care
- MAC Real Estate
- Exchange
- BPMC Nasdaq
- MAC Nasdaq
- Market Cap
- BPMC 5.8B
- MAC 5.1B
- IPO Year
- BPMC 2015
- MAC 1994
- Fundamental
- Price
- BPMC $84.69
- MAC $14.68
- Analyst Decision
- BPMC Buy
- MAC Hold
- Analyst Count
- BPMC 22
- MAC 12
- Target Price
- BPMC $124.48
- MAC $18.62
- AVG Volume (30 Days)
- BPMC 1.2M
- MAC 2.8M
- Earning Date
- BPMC 05-01-2025
- MAC 04-29-2025
- Dividend Yield
- BPMC N/A
- MAC 4.64%
- EPS Growth
- BPMC N/A
- MAC N/A
- EPS
- BPMC N/A
- MAC N/A
- Revenue
- BPMC $508,824,000.00
- MAC $899,298,000.00
- Revenue This Year
- BPMC $45.70
- MAC $1.69
- Revenue Next Year
- BPMC $31.83
- MAC N/A
- P/E Ratio
- BPMC N/A
- MAC N/A
- Revenue Growth
- BPMC 104.04
- MAC 5.01
- 52 Week Low
- BPMC $73.04
- MAC $12.48
- 52 Week High
- BPMC $121.90
- MAC $22.27
- Technical
- Relative Strength Index (RSI)
- BPMC 47.15
- MAC 41.01
- Support Level
- BPMC $78.66
- MAC $13.40
- Resistance Level
- BPMC $83.50
- MAC $17.94
- Average True Range (ATR)
- BPMC 5.00
- MAC 1.11
- MACD
- BPMC 0.20
- MAC -0.02
- Stochastic Oscillator
- BPMC 67.15
- MAC 40.29
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
About MAC Macerich Company (The)
The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.